Contrasting Burning Rock Biotech (BNR) & The Competition

Burning Rock Biotech (NASDAQ:BNR – Get Free Report) is one of 842 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Burning Rock Biotech to related companies based on the strength of its institutional ownership, risk, analyst recommendations, dividends, valuation, profitability and earnings.

Profitability

This table compares Burning Rock Biotech and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Burning Rock Biotech -13.60% -12.98% -8.59%
Burning Rock Biotech Competitors -12,516.26% -215.91% -31.70%

Volatility & Risk

Burning Rock Biotech has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, Burning Rock Biotech’s rivals have a beta of -1.85, indicating that their average share price is 285% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Burning Rock Biotech and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Burning Rock Biotech 1 0 0 0 1.00
Burning Rock Biotech Competitors 9915 15326 45725 1601 2.54

As a group, “Biotechnology” companies have a potential upside of 109.00%. Given Burning Rock Biotech’s rivals stronger consensus rating and higher probable upside, analysts plainly believe Burning Rock Biotech has less favorable growth aspects than its rivals.

Insider and Institutional Ownership

30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Burning Rock Biotech and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Burning Rock Biotech $514.43 million -$7.92 million -15.02
Burning Rock Biotech Competitors $728.85 million $9.97 million -18.46

Burning Rock Biotech’s rivals have higher revenue and earnings than Burning Rock Biotech. Burning Rock Biotech is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Burning Rock Biotech rivals beat Burning Rock Biotech on 7 of the 13 factors compared.

Burning Rock Biotech Company Profile

(Get Free Report)

Burning Rock Biotech is a precision oncology company that develops and provides next-generation sequencing tests for cancer. Its testing uses tissue and blood samples to help inform treatment decisions, monitor disease and support cancer research. The company also provides research and clinical-trial services to pharmaceutical companies, including support for the development of cancer therapies and diagnostic tests. Burning Rock is headquartered in Guangzhou, China, and its business primarily serves the Chinese healthcare and life sciences markets.

Receive News & Ratings for Burning Rock Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Burning Rock Biotech and related companies with MarketBeat.com's FREE daily email newsletter.